SARS-CoV-2 triggers the production of the antiviral protein IFN-γ associated with fatigue, muscle ache, and depression in Long COVID patients. Research by the University of Cambridge identifies IFN-γ as a potential biomarker for fatigue and a target for therapies. Persistent production of IFN-γ was found in patients up to 31 months post-infection. The study followed Long COVID patients for 2.5 years, highlighting the need for effective treatments. Vaccination was found to decrease IFN-γ levels in patients with resolved symptoms. Understanding IFN-γ could help classify Long COVID subtypes for personalized treatment and provide insights into potential therapies for future pandemics.
Source link
Identifying antiviral protein IFN-γ as a potential biomarker for Long COVID
